Loading...
Market
Will Organon meet the first sales milestone for VTAMA Cream by December 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Organon's quarterly financial reports and press releases
Story
Organon Acquires Roivant's Dermavant for $1.2 Billion, Including VTAMA Cream
Sep 18, 2024, 11:36 AM
Organon has announced its acquisition of Dermavant, a subsidiary of Roivant Sciences ($ROIV), in a deal valued at $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The deal involves an upfront payment of $175 million, with additional payments up to $1.2 billion contingent on sales milestones and approval in atopic dermatitis. This acquisition underscores Organon's commitment to expanding its portfolio in dermatology.
View original story
Similar markets
Yes • 50%
No • 50%
None • 25%
Up to $200 million • 25%
$200 million to $600 million • 25%
Above $600 million • 25%
Less than $500 million • 25%
$500 million to $799 million • 25%
$800 million to $1 billion • 25%
More than $1 billion • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
